Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. - Wikidata - awgldk - TriplyDB

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

http://www.wikidata.org/entity/Q40908899

about

Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and Prognosis Pre- and Post-Transplant Antiviral Therapy (HBV, HCV)Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease Approved Antiviral Drugs over the Past 50 Years Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C Treatment optimization for HIV/HCV co-infected patients.Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure.Hepatitis C virus infection.Impact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: a systematic review and meta-analysis.The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma.Virologic Cure of Hepatitis C: Impact on Hepatic Fibrosis and Patient Outcomes.The expanding spectrum of HCV-related cryoglobulinemic vasculitis: a narrative review.Hepatitis C treatment: where are we now?Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals.Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.Long-term outcomes of heart transplant recipients with hepatitis C positivity: the data from the U.S. transplant registry.Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.New Therapies for Hepatitis C Virus Infection.Hepatitis C in a New Era: A Review of Current Therapies Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.Hepatitis C Virus and Liver Transplantation.Immunological Predictors of Nonresponse to Directly Acting Antiviral Therapy in Patients With Chronic Hepatitis C and Decompensated Cirrhosis.Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis.Epidermal Growth Factor Receptor-Dependent Mutual Amplification between Netrin-1 and the Hepatitis C Virus.Retinoid derivative Tp80 exhibits anti-hepatitis C virus activity through restoration of GI-GPx expression.Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium New perspectives for preventing hepatitis C virus liver graft infection.Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV Morbidity and Mortality Among Community-Based People Who Inject Drugs With a High Hepatitis C and Human Immunodeficiency Virus Burden in Chennai, India.Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin.Serum Fibrosis Markers for the Diagnosis of Liver Disease Among People With Chronic Hepatitis C in Chennai, India.Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.

P2860

Q26740313-5BBBD768-FD05-44DC-897E-311C980410BB Q26740319-E8DCCC8C-F9C3-461E-B7E8-DA63FC2EC6BD Q26746563-93BB0EDE-07A5-41C2-BD49-FDD2596D5723 Q26751452-1B0F4B6A-6F85-4659-908F-E289B887DF1A Q26752433-89EC4640-BAAB-4436-BEFD-73AB6195E138 Q27755387-3869E6D3-9878-4120-9801-039E9607852D Q28067411-09E0296D-61D1-462B-B411-2A968A9A7014 Q28075544-16FB5BAC-6835-48C0-8EB0-3757F808F84B Q28076883-4EE59F9A-0242-4484-85DB-93A8657CA98A Q28080225-E59F8208-E8A7-41B9-BDAF-F27AF48BF483 Q30235034-DA01330A-EC3A-4773-AFD4-691F609A0272 Q30235178-A7B1FF53-388B-49AF-99E0-00F182214865 Q30235430-9ED2C9FD-0387-4FB5-8AFB-E8EE35777E4D Q30235491-46A842EE-E897-4097-B675-2F74B631CB40 Q30241048-7ABBD22D-4CCA-47CA-BCFC-39CE3A3C2675 Q30250096-9CC027F5-66AB-496E-A030-3FA158B9C9BC Q30250322-561E87EF-D15F-404C-BC07-DD33DF3498BF Q30251847-D0A85244-3870-4682-9BF4-ADB179860C0F Q30378509-7C61FAE9-C3CA-4264-8093-C047BD40D214 Q30386551-210DB555-D09F-4945-A225-76703952FA9E Q31051529-2AF62DA1-FCEF-4E63-A2DC-423C6F4F58DA Q31136569-D57AF05D-CAB9-48FE-A2CC-7CEE1504E5DC Q31160142-7ABE3848-39C1-4B0A-B049-B750356EAB54 Q33557819-A788CFDE-C0AA-4C42-8540-982761BE3FCC Q33560181-4354F16B-DCA0-4D29-A810-CF68127D1499 Q33585021-C2ACE4F7-66BB-4D3E-956D-0598D2399D13 Q33703634-B84569B8-6596-40DB-ACB7-9856AFCE8616 Q33717116-0D42BF42-B4BF-45BC-86FE-7A82EB7007B2 Q33745372-74FD582E-B687-4002-B9F9-67045A12361D Q34522481-B2B10931-DFDB-4D9C-A429-CD9A04E1E179 Q35975438-981EC90C-A432-4567-BE7D-FCA92F90815E Q36214085-12157336-86C2-4519-8F9E-9F88E266503B Q36261373-8BDC5047-A0B8-4DDE-8DCC-AFD04349CC47 Q37015805-4C15270C-9FC7-4360-A0B4-1B426126CCF1 Q37055231-A70456EE-307B-4156-82A3-C91AE46D4516 Q37089469-AAE5DD26-7104-4986-96AB-552C32865432 Q37298739-D319DD96-F963-4498-92E1-69A32C92A01C Q37305630-604897F0-0896-408E-AABE-546F8E817DD2 Q37349067-D7BD1DC9-A163-4D75-8DD2-B1F387A0D802 Q37398996-DD7CA5F3-7E15-40F5-912D-EE0D53C7087D

P2860

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

http://www.wikidata.org/entity/Q40908899

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

@en

type

label

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

@en

prefLabel

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

@en

P1433

Q40908899-29A36A43-232A-490B-9561-4DD6629964CD

P1476

Q40908899-731D565E-5E4E-4CC9-90FB-311AD81726E5

P2093

Q40908899-026D0E58-81ED-4052-AB3E-528DA69B7BED

Q40908899-0EBC5468-D526-4097-AFA6-FF7D223E52F3

Q40908899-207B5D82-9D91-43FF-88DC-BF2D8958A718

Q40908899-2240D2A2-4A9F-4277-BAF4-B4F8336C2982

Q40908899-2DF7EEF6-C3EB-4EAF-B987-3A62984F1446

Q40908899-33394556-5E32-4EEE-A250-56D447C47AA0

Q40908899-4BA8C6F1-578A-4C44-98E4-F45AD2467460

Q40908899-6F21F621-65D3-4DFA-A493-8B268AA14C8C

Q40908899-7BEB29A9-C3C0-4002-8694-9B58FF9744BB

Q40908899-8870727A-5C3B-49D7-ACE2-368D5578B9B1

P304

Q40908899-3319C412-C85E-43DE-BD79-C071F0D0587D

P31

Q40908899-90FDBF46-B7E4-4ABB-BC67-AEFFF62EC41A

P356

Q40908899-254F6272-411B-41AA-A067-DB6E5E2A435F

P407

Q40908899-AD52C2DE-A042-4F88-8D50-C6D8B5B1D554

P433

Q40908899-9CF00066-516F-4F3A-8991-DF55592E3F29

P478

Q40908899-F93234A9-FEC9-4BDE-A5C2-8A7D77D452C0

P50

Q40908899-D4F15428-D67A-447B-BC7E-1DB9C2FBCA84

P577

Q40908899-04D7FB95-60AE-4765-B73A-2FCC4FDD56A8

P698

Q40908899-16619E2D-6991-4ECC-A312-02EF14EA9FB7

P921

Q40908899-59E032E2-3745-4321-9940-A8E1DC83385C

Q40908899-9ECB75F8-BE0D-46D5-87A3-771A58D90AEC

P356

P1433

The New England Journal of Medicine

P1476

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

@en

P2093

ASTRAL-4 Investigators

http://www.w3.org/2001/XMLSchema#string

Andrew J Muir

http://www.w3.org/2001/XMLSchema#string

Anu Osinusi

http://www.w3.org/2001/XMLSchema#string

Brian Doehle

http://www.w3.org/2001/XMLSchema#string

Di An

http://www.w3.org/2001/XMLSchema#string

Diana M Brainard

http://www.w3.org/2001/XMLSchema#string

Eric Lawitz

http://www.w3.org/2001/XMLSchema#string

Eugene Schiff

http://www.w3.org/2001/XMLSchema#string

Jacqueline G O'Leary

http://www.w3.org/2001/XMLSchema#string

John G McHutchison

http://www.w3.org/2001/XMLSchema#string

P304

2618-2628

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1512614

http://www.w3.org/2001/XMLSchema#string

P407

P433

27

http://www.w3.org/2001/XMLSchema#string

P478

373

http://www.w3.org/2001/XMLSchema#string

P50

K. Rajender Reddy

P577

2015-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26569658

http://www.w3.org/2001/XMLSchema#string

P921